{"id":"W2556475996","doi":"10.1182/blood.v110.11.411.411","title":"Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Proteasome inhibitor; Bortezomib; Medicine; Dosing; Pharmacology; Multiple myeloma; Mantle cell lymphoma; Tolerability; Proteasome; Internal medicine; Lymphoma; Adverse effect; Chemistry; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008083193,0.001196031,0.001347218,0.0005534102,0.0003274944,0.0006006343,0.0007260027,0.001103245,0.002745663],"category_scores_gemma":[0.0005549216,0.0004896155,0.0005854459,0.0003038542,0.0005336979,0.0005646365,0.0002442459,0.002469968,0.0005681956],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008488909,"about_ca_system_score_gemma":0.0008992433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007704422,"about_ca_topic_score_gemma":0.002172926,"domain_scores_codex":[0.9997036,0.0001022019,0.00001113279,0.00005830351,0.00003716622,0.00008763393],"domain_scores_gemma":[0.9996568,0.00005119335,0.00008074386,0.00003379252,0.00002750181,0.0001499449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3312032,0.1531889,0.004846758,0.0007987901,0.0004651208,0.0003319037,0.0004115876,0.005351915,0.3021837,0.0006531083,0.008708799,0.1918563],"study_design_scores_gemma":[0.1078962,0.8441221,0.01109105,0.00002523886,0.0001542115,0.0003306514,0.00004202293,0.001438164,0.02980589,0.0001889355,0.004879518,0.00002585138],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933361,0.001459577,0.0005454955,0.0002343441,0.000105254,0.002071239,0.0008039394,0.0001354944,0.001308454],"genre_scores_gemma":[0.9906722,0.001017798,0.001329713,0.0002845126,0.00008402289,0.002310015,0.001545627,0.00002664596,0.002729561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002745663,"threshold_uncertainty_score":0.009185135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01962206881790056,"score_gpt":0.259396809851684,"score_spread":0.2397747410337834,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}